IDEXX Laboratories (NASDAQ:IDXX) Posts Earnings Results, Beats Estimates By $0.33 EPS

IDEXX Laboratories (NASDAQ:IDXX) released its quarterly earnings results on Tuesday. The company reported $4.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.94 by $0.33, Zacks reports. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.During the same period in the prior year, the firm posted $3.50 earnings per share. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories updated its FY 2026 guidance to 14.690-14.940 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• Strong second-quarter performance: Revenue grew 10% reported and 9% organically, while comparable EPS increased 15% to $4.27. IDEXX raised its full-year revenue outlook to $4.70 billion–$4.745 billion and EPS outlook to $14.69–$14.94.
• CAG Diagnostics recurring revenue grew 10.3% organically, including nearly 10% growth in the U.S. and nearly 12% internationally, driven by testing volumes, customer additions, instrument placements and higher utilization.
• Innovation momentum remained strong, with 1,602 inVue Dx placements in the quarter and 2,700 year-to-date, keeping the company on pace for its 5,500-unit annual goal. The controlled rollout of inVue Dx FNA is expanding in the third quarter, with broad availability planned by year-end, while Cancer Dx surpassed 10,000 ordering clinics.
• U.S. same-store clinical visits declined 1.3%, with wellness visits down nearly 3%, and IDEXX expects a similar approximately 1.5% decline in the second half. Management cited consumer economic pressure and slower pet adoption trends as ongoing constraints.
• Comparable operating margin expanded 110 basis points to approximately 35% in the second quarter, but IDEXX plans additional commercial, R&D, IT and AI investments in the second half. The company also expects foreign exchange to create a $15 million full-year revenue headwind, partly offsetting operational improvements.

IDEXX Laboratories Stock Up 3.8%

IDEXX Laboratories stock traded up $21.82 during midday trading on Tuesday, reaching $589.66. The stock had a trading volume of 373,352 shares, compared to its average volume of 577,157. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories has a 12 month low of $518.55 and a 12 month high of $769.98. The company has a fifty day moving average price of $557.53 and a two-hundred day moving average price of $588.43. The company has a market capitalization of $46.51 billion, a P/E ratio of 43.62, a PEG ratio of 3.06 and a beta of 1.54.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in IDXX. State Street Corp boosted its stake in IDEXX Laboratories by 4.0% during the 4th quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after purchasing an additional 138,956 shares during the last quarter. Invesco Ltd. increased its position in shares of IDEXX Laboratories by 13.8% during the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after purchasing an additional 181,955 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in IDEXX Laboratories by 37.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 952,223 shares of the company’s stock worth $644,208,000 after buying an additional 258,015 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of IDEXX Laboratories by 318.1% in the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after purchasing an additional 592,834 shares during the period. Finally, Amundi raised its stake in shares of IDEXX Laboratories by 4.4% in the fourth quarter. Amundi now owns 618,743 shares of the company’s stock valued at $418,598,000 after buying an additional 26,144 shares during the period. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on IDXX. UBS Group reduced their price target on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating on the stock in a research report on Monday, July 27th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Finally, Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $749.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.